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How many genes to make a higher vertebrate?
Recently, the number of genes encoded in the human genome has been estimated to lie
between 30-40.000. This estimate is much lower than was previously expected and compares to
around 15.000 genes in the fruitfly Drosophila melanogaster and around 20.000 genes in the
nematode Caenorhabditis elegans genome. Most people assumed that during evolution increases in
the size and complexity of organisms would be achieved by a substantial increase in the number of
genes through gene duplication events. These newly duplicated genes would then diverge from its
ancestor through accumulation of mutations and many of their gene products would contribute to new
biological functions. It has become clear from the sequence of the human genome that our increased
biological complexity is not accommodated by a multifold increase in genes that execute all these new
biological functions. Instead, many gene products are “recycled” to serve different functions at
different times and places in a higher organism. Re-used gene products can mediate new biological
features by functioning in a different cellular context, in which their function is dependent on the
presence of other gene products that modify their effects. Also, newly duplicated genes could serve a
wide range of new functions due to co-evolution of their regulatory elements. Mutations of these
elements would allow new spatio-temporal expression of these genes to execute functions in cells that
did not express the ancestor gene. However, many duplicated genes remain expressed in a similar
spatio-temporal fashion and retain functions that largely resemble that of the ancestor gene. This may
account for the frequent observations in higher vertebrates where the loss of gene A does not lead to a
phenotype. In those cases a highly related gene B compensates for its loss towards a certain biological
effect. This phenomenon is referred to as functional redundancy.
Any old Trk will do?
Throughout mouse nervous system development neurons receive stimuli from their
environment that steer their cell fate decisions, make them migrate, proliferate, differentiate, survive
or die. Members of the neurotrophin family of polypeptide ligands bind to and activate their
respective Trk receptors to provide one such stimulus (Chapter 1). The highly similar Trk receptors,
TrkA, TrkB and TrkC, are expressed in overlapping and distinct neurons in the peripheral and central
nervous system and their activation may lead to many of the abovementioned effects. Biochemical
studies in cell lines have sofar not revealed any protein that is activated by one specific Trk receptor
and not by the others. This and the high degree of conservation between the Trk receptors suggest that
each receptor type generates an identical signal in every neuron in which it is expressed. Moreover, if
a cell expresses several Trk receptors the loss of one type of receptor would not have a detrimental
effect, since signals from the other expressed Trk receptor can fully compensate for this loss.
However, evidence reviewed in Chapter 1 suggested that different neurotrophin-Trk
interactions might have a different biological outcome. Are these observations explained by the fact
that different neurons respond to a Trk-mediated signal differently? Or could it be that signals
emanating from activated Trk receptors are not identical? In this thesis we asked whether TrkB and
TrkC, two members of the Trk receptor family, (1) transduce similar signals in neurons co-expressing
these receptors and (2) whether identical signals and biological effects are generated in different TrkB
or TrkC expressing neurons. For this purpose, we generated a point mutation in trkC in the mouse
germline (trkCshc/shc; Chapter 2) and compared the effects of this mutation to a similar point mutation
in trkB (trkBshc/shc; (Minichiello et al., 1998)). The mutated juxtamembrane tyrosine residue binds the
Shc and FRS2 adaptor proteins and is thought to be pivotal in mediating neurotrophin-induced cell
survival and differentiation (Stephens et al., 1994) (Atwal et al., 2000).
In Chapter 3 we show that in primary embryonic cortical neurons derived from trkCshc/shc mice
the adapter proteins Shc and FRS2 no longer bind to the mutated residue in TrkC. However, another
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adapter known to bind a phosphorylated tyrosine in the Trk receptor intracellular domain, PLCγ, can
still interact with this receptor. When we tested the effects of the mutation on signalling cascades
activated downstream of the receptor, we found that phosphorylation of the Akt and Erk1/2 kinases
was only partially affected. These results were similar to the effects observed in trkBshc/shc neurons.
These results show that the effects of the mutation on well-described downstream signalling pathways
are rather mild and that TrkB and TrkC are similarly affected by the mutation. Surprisingly, the
mutations did reveal a difference between the receptors: in TrkB the Shc-binding site is the major
autophosphorylation site, while ligand induced autophosphosphorylation is hardly affected in
TrkCshc/shc neurons. This reduced phosphorylation of the TrkBshc/shc receptor correlated with a shorter
lasting interaction of PLCγ with TrkB.
In Chapter 4 and Chapter 5 we comparatively analysed neuronal survival, differentiation and
target innervation in the well-studied inner ear ganglia of both mutant strains of mice. It was found
that the effects on cell survival were mild and similar between the TrkB-dependent vestibular neurons
and the TrkC-dependent cochlear neurons in trkBshc/shc and trkCshc/shc mice, respectively. In contrast,
target innervation was progressively reduced in TrkBshc/shc vestibular neurons, but not in TrkCshc/shc
cochlear neurons. In order to determine whether these characteristics are specific to these neuronal
subtypes or shared with other TrkB and TrkC-expressing neurons, we studied survival and target
innervation in TrkB-dependent baroreceptive neurons and in TrkC-dependent proprioceptive and
mechanoceptive neurons (Chapter 6). As in the inner ear, survival was affected similarly in neurons of
both mutant mice, whereas target innervation is lost in trkBshc/shc, but not in trkCshc/shc neurons.
We previously reported that in trkBshc/shc mice the two TrkB ligands BDNF and NT4 had
differential effects on cell survival: all NT4-dependent neurons were lost, whereas only a minority of
BDNF-dependent neurons died. This difference was found to correlate with a reduced ability of NT4
compared to BDNF to phosphorylate the Erk1/2 MAP kinases in trkBshc/shc neurons (Minichiello et al.,
1998). This could mean that stimulation by BDNF, but not NT4 recruits a cofactor that somehow
compensates for the loss of the signal transduction events downstream of the Shc binding site. Since
no such factor has been found, we favour that the two ligands bind the two TrkB monomers
differently. This would lead to a different activation mechanism, which is exposed by the point
mutation. In Chapter 7 we asked whether this remarkable difference in biological activity is absolute,
or whether it is dependent on the cellular context in which the ligands mediate cell survival. The
ability of both BDNF and NT4 to rescue transected facial motorneurons was tested in trkBshc/shc
mutant mice. BDNF-mediated rescue is halved in trkBshc/shc compared to wild-type neurons. NT4 has
an intrinsically lower ability to rescue these neurons, but remarkably, this NT4-mediated rescue is
unaffected by the mutation.
In conclusion, we show that TrkB and TrkC promote survival of sensory neurons mainly
through Shc site-independent pathways, suggesting that these receptors use similar pathways to
prevent apoptosis. In contrast, the regulation of target innervation appears different: in trkBshc/shc mice
neurons lose target innervation, whereas in trkCshc/shc mice the surviving TrkC-dependent neurons
maintain target innervation and function. Most notably, these phenotypes appear independent of the
cellular context. Our biochemical analyses indicate that the mechanism by which the intracellular
domains of TrkB and TrkC are phosphorylated are however different. We argue that, these differences
underlie how the two highly similar receptors achieve their overlapping and distinct biological
functions. Further structural and biochemical studies will have to shed light on how the TrkB and
TrkC homodimers are activated after binding their respective ligands.
In a similar vein, the trkBshc/shc mutation has previously provided evidence that TrkB is
differently activated by its two ligands, BDNF and NT4, as determined by the effects of the mutation
of TrkB-mediated cell survival (Minichiello et al., 1998) (Fan et al., 2000). Having tested both ligands
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in a neuronal lesion based assay for TrkB-mediated cell survival in trkBshc/shc mice, we find that the
previously reported differences could be dependent on the cellular context. For instance, external
stimuli available to the lesioned motoneurons, but not developing sensory neurons or variations in
availability of signal mediators could account for our observations. Again, further work will have to
show how the two ligands are able to activate TrkB in different ways to mediate neuronal survival.
Evolutionary aspects.
It is thought that the neurotrophin gene family has evolved through two separate gene
duplications of a putative ancestor in an early vertebrate lineage. The first is thought to have separated
the NGF/NT3 and BDNF/NT4 pairs. The second duplication is thought to have happened after the
emergence of the jawless fish (like the river lamprey) around 460 million years ago, but before the
divergence of bony fish 400 million years ago (Hallbook, 1999). Strikingly, phylogenetic analyses of
the Trk receptors have suggested that the ligands and receptors have co-evolved. So why have higher
vertebrates co-evolved these molecules? Sofar, analysis of the nematode Caenorhabditis elegans and
the fruitfly Drosophila melanogaster have not revealed functional neurotrophins or their receptors,
although they do appear to possess other receptor tyrosine kinase families like the EGF, FGF, PDGF
and VEGF receptors and corresponding ligands. However, both organisms have nervous systems of
reasonable complexity suggesting that neurotrophins were an evolutionary later invention to
accommodate a further increase in nervous system intricacy. Both comparative expression analysis
and mutation rate analysis of neurotrophins and Trk’s has revealed that the NT3/TrkC pair likely
represents the closest relative of the archetypical pair. NT3 is highly conserved and NT3/TrkC are
expressed earlier during ontogeny and in more non-neuronal tissues than the other neurotrophin-
receptor pairs. Later diverging neurotrophins and receptors would acquire altered regulation of their
expression in order to execute their functions later in development and in different tissues. All this
reinforces the idea that “new” neurotrophin-receptor pairs were employed to make evolutionary newer
structures receptive to different neurotrophins to mediate biological functions. In short, they would
respond to a survival or differentiation signal without confusing other nearby cells expressing
different neurotrophins receptors. It is conceivable, for instance, that sensory neurons in the DRG
sensitive to different modalities would need to use different ligand-receptor pairs in order to maintain
their innervation specificity.
So, does it matter for a neuron which neurotrophin and receptor it uses to survive, differentiate
or to guide its axon to the correct target? Trk receptors apply similar downstream signalling pathways
to mediate their overlapping and distinct biological functions. Our studies show however, that two of
the Trk receptors use different mechanisms to activate downstream signalling pathways after ligand
binding. Trk’s may use common signalling pathways to mediate for instance cell survival, whereas
differences in their signalling mechanisms could account for biological activities specific to each of
the Trk receptors. Thus, the multiplication of the neurotrophin ligand-receptor pairs may not simply
have aided to separate messages for a specific neuronal population, but also have allowed for distinct
biological effects to be signalled to specific neurons.
Future perspectives
Much of the initial euphoria surrounding the neurotrophins was centered on their ability to
provide cells with a survival signal during development. Subsequent studies showed in a variety of
paradigms for neuronal damage that endogenous levels of neurotrophins were upregulated and that
exogenously added neurotrophins could aid the survival of specific neurons (Olson, 1993) (Sofroniew
et al., 2001). Neurotrophins and their receptors are nowadays seen as a relevant point of clinical
intervention in neurodegenerative diseases, neuropathies, pain, and even depression and cancer (e.g.
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(Altar, 1999) (Jones et al., 2001). The clear involvement of BDNF/TrkB in synaptic plasticity,
learning and memory in the adult nervous system (McAllister et al., 1999) (Kafitz et al., 1999)
(Minichiello et al., 1999) has even made neurotrophins a possible target for a “smart drug”!
An obvious starting point would be the different neurotrophic factors proteins or
pharmacological agents that mimic specific neurotrophins. Despite beneficial effects in animal models
of disease, clinical trials using neurotrophins have not lived up to expectation (Saragovi and Gehring,
2000). This is thought to be due to the fact that large polypeptides are generally poor drugs.
Development of neurotrophin mimetics may alleviate some of the pharmacological and
pharmacokinetic obstacles (Xie and Longo, 2000).
Another clear problem with these pleiotropic factors is that many unwanted side effects may
occur when used widely or even systemically. For instance, adding a neurotrophin may rescue a spinal
motoneuron from degenerating, but make a nearby sensory neuron change its sensitivity to pain and
affect neurons in the brain leading to reduced appetite. In addition, many neurotrophin are expressed
in various cell types outside the nervous system, adding to the list of possible side effects (Tessarollo
et al., 1993) (Saragovi and Gehring, 2000). These and the above mentioned problems are being
addressed by improving the means of delivery. Gene therapy and stem cell therapy (Jones et al., 2001)
(Gage, 2000). This could help restrict unwanted effects by transplantation of exogenous cells that are
made to produce neurotrophins near the site of action. But even in those cases no real specificity
towards the site of action and towards a biological effect can be assured. Ideally, a specific Trk
receptor would be activated in order to mediate a specific biological effect only on a particular group
or type of cells. So far, apart from the delivery specificity, the Trk extracellular ligand binding site is
the only site where a drug could work receptor specifically. Indeed, no evidence exists for an
intracellular modulator specific for a Trk-mediated biological effects or for individual Trk’s. Our data
show that TrkB and TrkC are activated differently by their ligands BDNF and NT3 and that TrkB is
activated in a different way by its ligands BDNF and NT4. These results may prompt renewed efforts
to determine the exact nature of Trk receptor activation in order to find molecular of structural
specificity in targeting neurotrophin signalling.
